Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Dividends Paid - Common: 2021-2025

Historic Dividends Paid - Common for Ani Pharmaceuticals (ANIP) over the last 4 years, with Sep 2025 value amounting to $344,000.

  • Ani Pharmaceuticals' Dividends Paid - Common fell 15.27% to $344,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 3.82%. This contributed to the annual value of $1.6 million for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Dividends Paid - Common is $344,000, which was down 15.48% from $407,000 recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Dividends Paid - Common registered a high of $407,000 during Q2 2022, and its lowest value of $190,000 during Q4 2021.
  • In the last 3 years, Ani Pharmaceuticals' Dividends Paid - Common had a median value of $406,000 in 2025 and averaged $400,636.
  • Per our database at Business Quant, Ani Pharmaceuticals' Dividends Paid - Common skyrocketed by 114.21% in 2022 and then fell by 15.27% in 2025.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Dividends Paid - Common stood at $190,000 in 2021, then surged by 114.21% to $407,000 in 2022, then decreased by 0.25% to $406,000 in 2023, then remained steady at $406,000 in 2024, then fell by 15.27% to $344,000 in 2025.
  • Its Dividends Paid - Common stands at $344,000 for Q3 2025, versus $407,000 for Q2 2025 and $406,000 for Q1 2025.